Psychopharmacology
February 1, 2011
Herbert Y. Meltzer, Masakuni Horiguchi, Bill W Massey
To review the evidence that agents which preferentially affect serotonin (5-HT) attenuate the ability of N-methyl-D-aspartate (NMDA) receptor non-competitive antagonists (NMDA-RA), e.g., phencyclidine (PCP), dizocilpine (MK-801), and ketamine, to stimulate locomotor activity (LA), and to impair novel object recognition (NOR). NMDA-RA-induced increased LA and impairment of NOR are widely used...
Journal of Neurochemistry
March 1, 1990
J. Frank Nash, Herbert Y. Meltzer, Gary A. Gudelsky
Abstract: The effect of the racemic mixture of 3,4‐methy‐lenedioxymethamphetamine (MDMA) on the synthesis of dopamine in the terminals of nigrostriatal and mesolimbic neurons was estimated by measuring the accumulation of 3,4‐dihydroxyphenylalanine (DOPA) in the striatum and nucleus accumbens 30 min following the administration of the l‐aromatic amino acid decarboxylase inhibitor,...
Pharmacology, biochemistry, and behavior
August 1, 1989
J F Nash, Herbert Y. Meltzer, Gary A. Gudelsky
40 citations
The repeated administration of 5-methoxy-N,N-dimethyltryptamine (5-MeODMT, 3 mg/kg, twice daily for 14 days) significantly diminished hypothermia and corticosterone secretion induced by an acute challenge with the 5-HT1A agonist 8-OH-DPAT (0.1 mg/kg) when compared to the responses in animals treated chronically with the solvent vehicle. In contrast, the chronic administration of 5-MeODMT did...
Life Sciences
1989
Ramesh Arora, Herbert Y. Meltzer
175 citations
3H-Lysergic acid diethylamide (3H-LSD) binding, a putative measure of 5-HT2 receptor binding, was studied in the blood platelets of 29 depressed patients and 24 normal controls. The Bmax (maximum number of 3H-LSD binding sites) in the blood platelets of depressed patients was significantly greater than that of normal volunteers. This increase in Bmax was due to an increase in female depressed...
Journal of Pharmacology and Experimental Therapeutics
June 1, 1988
Jr Jf Nash, Herbert Y. Meltzer, G. Gudelsky
The racemic mixture of 3,4-methylenedioxymethamphetamine (MDMA), which has been reported to produce selective destruction of serotonergic neurons in the central nervous system, was studied to determine its neuroendocrine and temperature effects and mechanism of action. MDMA elevated serum concentrations of corticosterone in doses ranging from 3 to 20 mg/kg administered i.p. Serum corticosterone...
Pharmacology, biochemistry, and behavior
March 1, 1985
Gary A. Gudelsky, J I Koenig, Herbert Y. Meltzer
54 citations
The incidence of "wet dog" shakes elicited by quipazine, the hyperthermic response induced by 5-methoxy-N,N-dimethyltryptamine (5MeODMT) and the hypothermic response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) were compared in rats of the Fawn-Hooded (FH) and Sprague-Dawley (SD) strains. The behavioral responses of FH rats to quipazine and 5MeODMT were significantly greater than...
Brain Research
August 8, 1983
Miljana Simonovic, Herbert Y. Meltzer
12 citations
5-Methoxy-N,N-dimethyltryptamine (5-MeODMT), a potent serotonin (5-HT) receptor agonist, exerts a biphasic effect on rat prolactin (PRL) secretion. 5-MeODMT (2.5-10 mg/kg) produces a marked, dose-related but short-lasting (less than 30 min) rise in serum PRL levels. At intervals longer than 30 min, 5-MeODMT (1-15 mg/kg) inhibits the stimulation of PRL secretion by another 5-HT agonist,...
European Journal of Pharmacology
October 15, 1979
Miljana Simonovic, Herbert Y. Meltzer
11 citations
Repeated administration of 5-methoxy-N,N-dimethyltryptamine (5MeODMT, 5 mg/kg, a serotonin agonist, every 3 h for a total of 4 injections) potentiated its prolactin (PRL)-releasing effect and that of two other serotonin agonists, quipazine and N,N-dimethyltryptamine. This pretreatment schedule had no effect on PRL response to anti-dopaminergic drugs. The onset of enhanced PRL response to...
Psychopharmacology
April 11, 1978
Herbert Y. Meltzer, Richard G. Fessler, Miljana Simonovic et al.
24 citations
The hallucinogenic indoleamine drugs N,N-dimethyltryptamine (N,N-DMT), psilocybin, bufotenin, 5-methoxy-N,N-dimethyltryptamine, and N-methyltryptamine, increased rat plasma prolactin (PRL) levels. The increase in plasma PRL produced by N,N-DMT, psilocybin, and bufotenin was inhibited by methysergide, a serotonin receptor blocker. Parachlorophenylalanine (PCPA), an inhibitor of serotonin...
Psychopharmacology
1977
Herbert Y. Meltzer, Richard G. Fessler, Miljana Simonovic et al.
Lysergic acid diethylamide (LSD), 0.05 mg/kg and 0.20 mg/kg, significantly decreased plasma prolactin (PRL) levels in male rats. LSD, 0.20 mg/kg, also inhibits the increase in plasma PRL levels produced by chlorpromazine (CPZ), 5 mg/kg, and alpha-methylparatyrosine (AMPT), 50 mg/kg, both of which interfere with dopaminergic inhibition of PRL secretion. LSD was more potent than methysergide, a...